MAPT and Alzheimer disease: At present, the most well-established biomarkers for AD include the evaluation of beta-amyloid peptides (Aβ1-42), total tau (t-tau), and phosphorylated-tau (p-tau) in the cerebrospinal fluid (CSF) as well as the identification of amyloid deposition in the PET scans [1].